Tumor immunotherapy: don't because of phoney denied li kui

The 2016-05-05

Source: health

Our reporter tan jia Wang Xiao rain /

The wei west event continued fermentation. On May 4, the second hospital comprehensive TingZhen armed police corps in Beijing. The hospital issued announcement said, because education reorganization, from now on, stop all foreign service temporarily.

In previous reports, the hospital is west wei implementation of tumor immunotherapy was branded a "false", said wei west used in DC - CIK therapy "is eliminated by foreign technology". Industry experts said that in the event of an wei is on the west, biological immunotherapy technology by hospitals effect exaggerated, but it will be biological immunotherapy with void treatment inappropriate, "does not deny that li kui because phoney. Biological immune therapy is an effective weapon for tumor treatment, is the future of cancer treatment, it cannot be denied". Purge current urgently needs to strengthen supervision, biological immune therapy to clinical application, let phoney nowhere to hide.

Synovial sarcoma treated remains a medical problem

The second hospital affiliated to zhejiang university school of medicine of doctor of vice director of center for bone and soft tissue tumor diagnosis and treatment oil, Dr Lin, synovial sarcoma is a highly malignant soft tissue tumors, accounts for 5% ~ 10% of soft tissue sarcoma, the number of cases were in the center with only more than ten cases. Found in young people, the disease occurs in the joints, limbs deep soft tissue masses as the main performance. Tumor invasive and metastatic are strong, transfer to the lymph nodes and blood vessels. At present, the synovial sarcoma preferred surgical treatment, the operation is difficult to eradicate tumor mainly radiotherapy combined with postoperative auxiliary. On these mature treatment effect, similar to international level in our country.

Oil, Lin said, synovial sarcoma of the other treatment include biological immunotherapy and targeted therapy such as whole body is in clinical trials, the effect of uncertainty, individual research institutions at home and abroad is still only have scattered research. Oil, Lin said, he is very understand wei said in hospitals is west a no cure, still the mood of melancholy expect a miracle. Many malignant tumors guidelines also recommend abroad, patients in the conventional treatment is invalid, can participate in clinical trials. Overall, the inefficiency of synovial sarcoma of the existing treatment, prognosis is poor. Patients involved in clinical trials of rigorous norms to try new treatments, may find a chance, also helps to promote medical progress. But in the experimental treatment, must follow the medical ethics, the protection of rights and interests of patients.

Biological immune therapy might be expected

For days, biological immunotherapy for wei is the death of the west in past. The interview, many experts point out that cannot be biased, negate tumor biological immunotherapy.

For "wei west DC to try - CIK therapy is obsolete biological immunotherapy technology abroad", tumor, southern medical university, director of the center for rong-cheng luo don't agree with. He introduces, dendritic cells (DC) therapy, cytokine induced killer cells (CIK) therapy has not been eliminated, currently in Japan, South Korea, Germany with CIK treatment of tumor, but for some tumor treatment have been negative, treatment effect and the choice of indications, cell preparation level, treatment plan design has a close relationship.

Peking University cancer hospital experts consultation center chief accurate diagnosis and consultation expert xi-xiong kang, biological immunotherapy has experienced more than 40 years development history, is now testing in melanoma, kidney, lung, and so on. At present, the global 76 pharmaceutical companies are investment field of biological treatment, also in constant progress.

In fact, in tumor field, is the strength of high biological immunotherapy. Science magazine voted in 2013 annual top ten scientific breakthrough in the cancer immunotherapy top. Rong-cheng luo said, a large number of clinical studies have shown that cell biological immune therapy to improve the cure rate of tumor, reduce the rate of tumor recurrence and metastasis. Associated with traditional treatments, can greatly improve the patients' survival, improve the patient's quality of life.

Peking University, vice President of the institute of clinical oncology guo pointed out that the world recognized tumor treatments including surgery, radiotherapy, chemotherapy, molecular targeted therapy and biological immunotherapy, which is the main research direction in recent years and has the breakthrough in PD - 1 is one of the representative. Guo pointed out at the same time, the DC, CIK therapy "story is very good but can't see the effect", it is not as clinical recommendations.

Lagging regulation of embarrassment

At present, the technology of the biological immunotherapy springing up across the country, some is not yet mature, the immune cells should be undertaken as a clinical research treatment is widely used in clinical, and expensive. Faced with some medical institutions for economic interests, the misuse of biological immunotherapy technology, regulation have the serious lag. Rong-cheng luo believe that relevant departments to "kick", is not capable regulation is the crux of the good and evil people mixed up in the area. Due to immune cells therapy is the treatment according to drug administration or according to technology management of the long-standing debate, the management of this field has been in regulatory limbo. No approval is arguably shouldn't charge for it, health care and prices there have been related to pricing. He suggested that, for the rapid development of biological immune therapy, the government should strengthen the supervision, as soon as possible out of the "whatever they are, a tube die" realistic dilemma.

Xi-xiong kang said that to develop effective, targeted biological immunotherapy. First of all need to establish objective laboratory evaluation system, detect in preoperative evaluation, "accurate" choice treatment object. "If a treatment technology has a 30% efficient, so patients should be assessed, at the early stage of the treatment to see if it covered within the scope of efficient." At the same time, to evaluate preoperative testing injected into the body of biological materials. Should assess whether the injected cells in the body after treatment, the results. In terms of prognosis evaluation, have the objective indicators. Now only depend on the patient feeling and doctor-patient communication, such as how appetite, mental state, such as no relatively objective indicators to measure. Foreign evaluation system is relatively limited at present, including the perception of patients with symptoms, imaging diagnostic and laboratory indexes, etc. In addition, for the new project should have standardized management, the management of the third class medical technology should have processes and procedures.

Xi-xiong kang said, biotherapy development too fast, agreed to appear before the new method, the domestic haven't specification process, consensus, and laws and regulations. In the process of such rapid development, more need to establish the basis of diagnosis and treatment system, emphasizes the multidisciplinary joint, is not only a medical, and legal and ethical issues. For tumor patients, at the same time, the treatment should have rational knowledge, some patients and family members are looking forward to the hospital is universal, this kind of unrealistic expectations, can bring more disappointed.